Solventum Corp. (SOLV)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $15.14B
Last updated: Nov 17, 2026 at 11:05 AM ET
Solventum Corp. (SOLV) Earnings: Report Dates and Results
Solventum (SOLV) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Solventum reported EPS of $1.45, above the $1.35 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SOLV has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 15.3% above the $1.57 reported for the quarter ended Dec 31, 2025.
SOLV Earnings Call
The latest SOLV earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 11 quarters below that had an estimate, SOLV beat 10 and missed 1. Revenue for the quarter ended Sep 30, 2026 was $1.95B, down 7.1% from $2.10B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.45 | $1.35 | $1.29 - $1.39 | +7.41% | Beat | -3.3% | 11 | 2 up, 0 down | Nov 5, 2026 | $1.95B |
| Jun 30, 2026 | $2.55 | $1.91 | $1.84 - $1.95 | +33.51% | Beat | +50.9% | 11 | 2 up, 1 down | Aug 5, 2026 | $2.21B |
| Mar 31, 2026 | $1.48 | $1.35 | $1.32 - $1.38 | +9.63% | Beat | +10.4% | 9 | 1 up, 0 down | May 5, 2026 | $2.01B |
| Dec 31, 2025 | $1.57 | $1.50 | $1.47 - $1.51 | +4.67% | Beat | +11.3% | 11 | 1 up, 0 down | Feb 26, 2026 | $2.00B |
| Sep 30, 2025 | $1.50 | $1.43 | $1.40 - $1.46 | +4.90% | Beat | -8.5% | 11 | 0 up, 0 down | Nov 6, 2025 | $2.10B |
| Jun 30, 2025 | $1.69 | $1.45 | $1.36 - $1.49 | +16.55% | Beat | +8.3% | 8 | 6 up, 1 down | Aug 7, 2025 | $2.16B |
| Mar 31, 2025 | $1.34 | $1.22 | $1.15 - $1.31 | +9.84% | Beat | -35.6% | 7 | 0 up, 2 down | May 8, 2025 | $2.07B |
| Dec 31, 2024 | $1.41 | $1.50 | N/A | -6.00% | Miss | -39.0% | 8 | 1 up, 0 down | Feb 27, 2025 | $2.08B |
| Sep 30, 2024 | $1.64 | $1.39 | $1.31 - $1.66 | +17.99% | Beat | N/A | 3 | 0 up, 1 down | Nov 7, 2024 | $2.08B |
| Jun 30, 2024 | $1.56 | $1.51 | $1.34 - $1.60 | +3.31% | Beat | N/A | 3 | 1 up, 0 down | Aug 8, 2024 | $2.08B |
| Mar 31, 2024 | $2.08 | $1.75 | N/A | +18.86% | Beat | N/A | N/A | N/A | May 9, 2024 | $2.02B |
| Dec 31, 2023 | $2.31 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 28, 2024 | $2.04B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $6.10, down 8.8% from the year before. It was $2.31 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $6.10 | -8.8% |
| Dec 31, 2024 | $6.69 | +189.6% |
| Dec 31, 2023 | $2.31 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,500 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,495 | 10 | |
| 2026Q2 | Jun 30, 2026 | 8,806 | 12 | |
| 2026Q1 | Mar 31, 2026 | 6,882 | 10 | |
| 2025Q4 | Dec 31, 2025 | 6,748 | 13 | |
| 2025Q3 | Sep 30, 2025 | 6,261 | 10 | |
| 2025Q2 | Jun 30, 2025 | 7,611 | 12 | |
| 2025Q1 | Mar 31, 2025 | 3,466 | 11 | |
| 2024Q4 | Dec 31, 2024 | 6,316 | 10 |
2026Q3 Earnings Call
Opening remarks
Amy Wakeham Senior Vice President of Investor Relations and Finance Communications Thank you. Good afternoon, and welcome to Solventum's Third Quarter Fiscal Year 2026 Earnings Call. Joining me on today's call are Chief Executive Officer Bryan Hanson and Chief Financial Officer Wayde McMillan. A replay of today's earnings call will be available later today in the Investor Relations section of our corporate website. The earnings press release and presentation are available there now. During today's call, our discussion and comments will be on a non-GAAP basis unless specifically identified as GAAP. The non-GAAP information discussed is not intended to be considered in isolation or as a substitute for reported GAAP financial information. Please review the supporting schedules in today's earnings press release to reconcile the non-GAAP measures with the reported GAAP numbers. Our discussion today will include forward-looking statements, including expectations about our future financial and operating performance. These statements are based on reasonable assumptions; however, our actual results could differ. Please review our SEC filings for a complete discussion of the risk factors that could cause our actual results to differ materially from any forward-looking statements made today. Following our prepared remarks, we'll hold a question-and-answer session. I'd now like to hand the call over to Bryan.
Bryan Hanson CEO All right. Thanks, Amy, and thanks to everyone for joining us today. Let me just start by saying that, in the third quarter, we executed the largest and most complex ERP cutover in the history of this company. Thankfully, it was also the last on our path to full separation. I can tell you from experience that a cutover at that scale is never seamless, and ours was no exception. But the mitigation plan that we built held, and this team delivered through it. To our customers, I want to say thank you for your partnership. You leaned in and worked with our teams, and that's what kept product moving to the patients who needed them. To our team specifically, this was a significant cross-functional effort. We had supply chain, IT, commercial, customer service, quality and finance all pulling in the same direction. That kind of team dynamic under that kind of team pressure isn't something you can just install. You either have it or you don't. We clearly have it. And speaking of having it, let's get into the quarter. All key financial metrics were in line with or ahead of our expectations, with organic growth and EPS both above plan. As we communicated in August, these results reflect the advanced orders reversing back out of the quarter following the ERP cutover. Once again, this team has proven that the say-do equation that we value so much is alive and well, regardless of the challenges around us.
Frequently Asked Questions About SOLV
When is Solventum's next earnings date?
Solventum's next earnings report is expected for Feb 24, 2027.
Did SOLV beat earnings estimates last quarter?
Yes. Solventum reported EPS of $1.45 for the quarter ended Sep 30, 2026, above the $1.35 estimate, a 7.41% surprise.
What EPS do analysts expect from SOLV next quarter?
The consensus EPS estimate for Solventum for the quarter ending Dec 31, 2026 is $1.81 from 14 analysts, with estimates from $1.72 to $1.90.
How often does SOLV beat earnings estimates?
Solventum beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +10.06%.
SOLV pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors